Jennifer Lin founded and leads Ashlins Pharmaceuticals, which develops overlooked therapeutic opportunities grounded in clinically validated biology and physician insight. A 2025 Thiel Fellow, she is advancing the AIS-001 program and treatments for rare diseases with limited patient access.